Market Place
Sourcing Support
BrainStorm`s ALS Drug Access Fought for By Patients Post
17 Jul 2025 //
BIOSPACE
BrainStorm Cell Therapeutics shifts to OTCQB from Nasdaq
17 Jul 2025 //
PR NEWSWIRE
FDA Reevaluates NurOwn®`s Treatment Effectiveness Evidence
09 Jul 2025 //
PR NEWSWIRE
BrainStorm Cell Therapeutics Announces Q1 2025 Financial Results
15 May 2025 //
PR NEWSWIRE
BrainStorm Therapeutics to Host Corporate Update Investor Call
09 Dec 2024 //
PR NEWSWIRE
BrainStorm Cell Therapeutics Names New EVP & COO
20 Jun 2024 //
CONTRACT PHARMA
BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design
27 Feb 2024 //
PR NEWSWIRE
BrainStorm Cell Therapeutics Announces Outcome of FDA Meeting on NurOwn® in ALS
07 Dec 2023 //
PR NEWSWIRE
BrainStorm Cell Therapeutics Announces In-Person Meeting with the FDA
20 Nov 2023 //
PR NEWSWIRE
BrainStorm Cell Therapeutics to Present at 6th Annual ALS Research Symposia
17 Nov 2023 //
PR NEWSWIRE
BrainStorm lays off 30%, details bid to reach ALS market
24 Oct 2023 //
FIERCE BIOTECH
BrainStorm eyes FDA meeting to find path for rejected drug
18 Oct 2023 //
FIERCE BIOTECH
FDA staff reviewers raise concerns over BrainStorm Cell`s ALS therapy
26 Sep 2023 //
REUTERS
BrainStorm Cell Therapeutics Announces Second Quarter 2023 Financial Results
14 Aug 2023 //
PR NEWSWIRE
Brainstorm Cell Announces Pricing of $7.5M Registered Direct Offering
17 Jul 2023 //
PR NEWSWIRE
BrainStorm Secures FDA Adcomm for ALS Therapy NurOwn
28 Mar 2023 //
BIOSPACE
BrainStorm Announces Promotion of Dr. Stacy Lindborg to Co-CEO
04 Jan 2023 //
PR NEWSWIRE
BrainStorm Cell Announces Type A Meeting with FDA Granted for NurOwn®
27 Dec 2022 //
PRNEWSWIRE
BrainStorm Cell Therapeutics Receives Refusal to File Letter from FDA
10 Nov 2022 //
PRNEWSWIRE
BrainStorm shares tumble as FDA again knocks back ALS drug
10 Nov 2022 //
FIERCEBIOTECH
BrainStorm Presents New Analyses from NurOwn`s Phase 3 ALS Trial
07 Nov 2022 //
PRNEWSWIRE
BrainStorm to Announce Third Quarter Results and Provide a Corporate Update
07 Nov 2022 //
PRNEWSWIRE
BrainStorm Presents Biomarker Analyses from NurOwn`s Phase 3 ALS Trial
07 Oct 2022 //
PRNEWSWIRE
BrainStorm Brings MS Data on Heels of ALS BLA Announcement (Updated)
16 Sep 2022 //
BIOSPACE
BrainStorm Publishes Results from the NurOwn PII MS Trial
15 Sep 2022 //
PRNEWSWIRE
ALS ‘Urgency’, US FDA Regulatory Environment Justify Filing NurOwn: BrainStorm
24 Aug 2022 //
PINK SHEET
Despite failed trial, Brainstorm asks FDA to approve ALS drug
16 Aug 2022 //
BIOPHARMADIVE
BrainStorm to Announce Second Quarter Results and Provide a Corporate Update
01 Aug 2022 //
PRNEWSWIRE
BrainStorm Announces Presentations at June 2022 Scientific Conferences
31 May 2022 //
PRNEWSWIRE
BrainStorm Cell Therapeutics Announces First Quarter 2022 Financial Results
16 May 2022 //
PRNEWSWIRE
BrainStorm Strengthens Executive Team with Key Appointments in R&D and Legal
12 May 2022 //
PRNEWSWIRE
BrainStorm Announces Presentation of NurOwn Exosome Preclinical Data at ISCT
04 May 2022 //
PRNEWSWIRE
BrainStorm to Announce First Quarter 2022 Financial Results
02 May 2022 //
PRNEWSWIRE
BrainStorm Cell Announces Full Year 2021 Financial Results
28 Mar 2022 //
PRNEWSWIRE
BrainStorm to Announce Q4 and Fiscal Year 2021 Financial Results
14 Mar 2022 //
PRNEWSWIRE
BrainStorm Cell Tx Abstract Selected at 2022 MDA Clinical, Scientific Conference
28 Feb 2022 //
PRNEWSWIRE
Brainstorm Cell Announces Grant of New Brazilian Patent on NurOwn
15 Feb 2022 //
PRNEWSWIRE
BrainStorm Cell & Catalent Announce Completion of Tec Transfer for NurOwn®
07 Dec 2021 //
PRESS RELEASE
BrainStorm, Catalent Announce Completion of Technology Transfer for NurOwn
07 Dec 2021 //
PRNEWSWIRE
BrainStorm to Present New Biomarker Data on NurOwn
02 Dec 2021 //
PRNEWSWIRE
BrainStorm Cell Therapeutics Announces the Presentation NurOwn®
29 Nov 2021 //
PRNEWSWIRE
ProtoKinetix Announces Selection of AAGP® Candidate Formulat Dry Eye Disease
23 Nov 2021 //
PRESS RELEASE
BrainStorm Cell Announces Q3 2021 Financial Results, Provides Corporate Update
15 Nov 2021 //
PRNEWSWIRE
Brainstorm Cell Therapeutics Appoints Menghis Bairu to Board of Directors
28 Oct 2021 //
PRNEWSWIRE
Phase 2 Trial Data of NurOwn in Progressive MS to be Presented at ECTRIMS
14 Oct 2021 //
PRNEWSWIRE
BrainStorm to Present ALS Phase 3 Biomarker Analyses at Annual NEALS Meeting
06 Oct 2021 //
PRNEWSWIRE
BrainStorm to Present at the 2021 Cell & Gene Meeting on the Mesa
04 Oct 2021 //
PRNEWSWIRE
BrainStorm Second Quarter Financial Results and Provide a Corporate Update
26 Jul 2021 //
PRNEWSWIRE
Brainstorm Announces Expansion of NurOwn® IP Portfolio
15 Jun 2021 //
PRNEWSWIRE
BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS
25 May 2021 //
PRNEWSWIRE
Despite red flag from FDA, controversial ALS cell therapy developer says it
23 Feb 2021 //
ENDPTS
After FDA feedback, a biotech`s ALS therapy faces murky path forward
22 Feb 2021 //
BIOPHARMADIVE
BrainStorm-Cell Therapeutics to Announce Fourth Quarter and Fiscal Year 2020
28 Jan 2021 //
PRNEWSWIRE
BrainStorm Announces the Publication of Preclinical Data Highlighting
20 Jan 2021 //
PRNEWSWIRE
BrainStorm Announces the Publication of Preclinical Data of a NurOwn®
20 Jan 2021 //
PRNEWSWIRE
BrainStorm Announces Completion of All Dosing in NurOwn® Phase 2 MS Study
18 Dec 2020 //
PRNEWSWIRE
BrainStorm initiates NurOwn Expanded Access Programme for ALS patients
15 Dec 2020 //
PHARMABIZ
BrainStorm to present NurOwn® Ph3 Trial Results at 31st Symposium on ALS/MND
23 Nov 2020 //
PRNEWSWIRE
BrainStorm Announces Topline Results from NurOwn® Phase 3 ALS Study
17 Nov 2020 //
PRNEWSWIRE
